Morphogenesis is a Phase 3 registration-stage immuno-oncology company based in Tampa, FL, specializing in developing novel technologies to overcome resistance to cancer immunotherapy. Their leading IFx technology focuses on personalized cancer vaccines to combat tumor resistance to immunotherapies like checkpoint inhibitors, with plans to initiate a Phase 3 trial for aggressive skin cancer in 2024. Additionally, they are utilizing their Delta technology to develop bi-functional antibody drug conjugates (ADCs) that target Myeloid Derived Suppressor Cells (MDSCs) and modulate their immunosuppressive effects on the tumor microenvironment, aiming to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in cancer treatment.
Morphogenesis is dedicated to overcoming two major obstacles that limit the effectiveness of cancer immunotherapies. They are advancing two proprietary technologies to address primary or innate resistance related to tumor intrinsic factors and secondary or acquired resistance resulting from highly immunosuppressive tumor microenvironments. Their IFx technology harnesses the power of the innate immune response by tricking the body's immune system to attack tumor cells, while their bi-functional ADCs leverage their Delta receptor technology to inhibit the immune suppressing effects of MDSCs, preventing T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
Generated from the website